Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Absci official news RSS · 行業原文收錄 · 來源發佈：Thu Sep 24 2026 12:00:49 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)
已保存的原文節選
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation
以上為帶出處的原文節選，完整內容請閱讀原始鏈接。自動收錄與主題分類不等於事實核驗。